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Introduction
Obesity is a major risk factor for the development of insulin resistance, type 2 diabetes and hepatic In this study, we investigated whether chronic oral BM administration in mice fed a HF diet for 21 weeks could prevent insulin resistance and liver injury in mice fed a HF diet. We also examined signalling molecules involved in insulin resistance, inflammation, and lipid metabolism in liver tissue. 
Materials and Methods

Animals and HF diet-induced obesity model
Glucose tolerance test
Mice were fasted overnight (16 hrs) before a glucose tolerance test (GTT) was performed to assess glucose clearance, following an intraperitoneal (i.p) injection of glucose (0.5 g/kg; Sigma-Aldrich, St Louis, MO). Blood samples were taken from the tail vein before and 30, 60 and 120 minutes following the injection of glucose. Blood glucose was measured using an Accu-Chek glucometer (Roche Diagnostics GmbH Mannheim, Germany).
Insulin sensitivity test
Mice were fasted for 5 hours before an insulin sensitivity test (IST) was performed to assess glucose clearance, following an i.p. injection of insulin (0.75 U/kg; Sigma-Aldrich, St Louis, MO). Blood samples were taken from the tail vein before and at 30, 60 and 120 minutes following the injection of insulin.
Blood glucose was measured using an Accu-Chek glucometer (Roche Diagnostics GmbH Mannheim, Germany).
Tissue collection and sample preparations
For tissue analysis, mice were euthanised at week 21 of the experiment. Tissue was dissected from the mice and immediately frozen in liquid nitrogen before being stored at -80 °C.
Oil Red O staining
Oil Red O staining was used to examine hepatic lipid accumulation as described previously ( 
Haematoxylin and Eosin (H&E) staining
To determine the degree of liver damage fresh frozen liver sections (10 μm) were stained with Haematoxylin and Eosin for 30 seconds each. Three fields from three sections of each mouse were viewed under a Leica microscope and digital photographs were captured. The histological parameters of steatosis and ballooning were scored according to the method described by Kleiner 
Immunohistochemistry
Liver sections fixed in 10% Formalin were embedded in paraffin before being sectioned (5 μm) onto Polylysine™ slides. Slides were incubated overnight at 4 °C with anti-rabbit F4/80 (1:150 Santa Cruz Biotechnology, Dallas, TX) diluted in blocking buffer as described previously . Three fields from three sections of each mouse were viewed under a Leica microscope and digital photographs were captured. Image J software was used to quantify the area of F4/80 immunoreactivity on each slide.
Extraction of nuclear and cytosolic proteins
Nuclear and cytosolic proteins were extracted from liver tissue as described by Mobasher et al 
Western Blot analysis
For total protein extraction, the frozen liver tissue was homogenised in Nonidet P-40 lysis buffer. The following antibodies were used for western blotting: Nrf2 (sc-722), IL-1β (sc-7884), IL-6 (sc-7920) and BDNF (sc-546) (Santa Cruz Biotechnology, Dallas, TX); pIKK (#2697), STAT3 (#4904), FOXO1 (#2880), SOCS3 (#2932), and PTP1B (#5311) (Cell Signalling Technology, Beverly, MA). Both nuclear and cytosolic protein levels of Nrf2 were analysed. The bands corresponding to the proteins of interest were scanned and the band density analysed using the automatic imaging analysis system, Quantity One (Bio-Rad Laboratories, Hercules, California) as described in our previous study . All quantitative analyses for total and cytosolic proteins were normalised to β-actin.
Nuclear proteins were normalised to Lamin B.
Luminex Assay
Blood was collected in EDTA tubes from mice following euthanasia. Following centrifugation, plasma was extracted, collected and stored at -80 °C. Plasma insulin levels were measured using Luminex assay kits according to the manufacturer's instructions (Bio-Rad Diabetes Kit, Sydney).
RNA isolation and RT-PCR
Total RNA was extracted from mouse liver using the Aurum total RNA mini kit (Bio-Rad Laboratories, Hercules, CA) before being reversed transcribed to complimentary first strand DNA with a high-capacity seconds. The expression of mRNA was normalised to an internal control, GADPH. The degree of mRNA expression was calculated using the comparative threshold cycle value (Ct) method, using the formula 2 -ΔΔCt (where ΔΔCt =ΔCt sample -ΔCt reference) as described previously (Livak and Schmittgen, 2001 ).
Statistics
Data were analysed using the statistical package SPSS 20 (SPSS, Chicago, IL). Data was first tested for normality using a Kolmogorov-Smirnov normality test. Differences between mice fed a LC, HF, and HF plus BM diet were then determined by one-way analysis of variance (ANOVA). This was followed by the post hoc Tukey-Kramer honestly significant difference (HSD) test for multiple comparisons among the groups. A p value of <0.05 was considered statistically significant. Values are expressed as the mean ± SEM.
Results
Bardoxolone methyl treatment prevented HF diet-induced insulin resistance
To explore the role of BM in glucose homeostasis and insulin sensitivity, glucose tolerance tests (GTTs) and insulin sensitivity tests (ISTs) were performed ( Figures 1A and C) . HF diet fed mice had significantly higher blood glucose levels during fasting (0 minute) and 120 minutes following an i.p.
injection of glucose compared to LC fed mice. However, administration of BM normalised blood glucose levels at 120 minutes in the GTT test in HF diet fed mice (-18.07%, p = 0.015), with significance confirmed with area under the curve (AUC) analysis ( Figure 1B) . However, BM did not prevent HF dietinduced increases in fasting blood glucose levels (p>0.05). Consistent with the effect of BM on improving glucose clearance, BM treatment also reduced blood glucose levels during the IST in mice fed a HF diet ( Figure 1C ). HF diet fed mice had significantly higher blood glucose levels at fasting and Fasting plasma insulin levels were examined to determine if BM could prevent HF diet-induced hyperinsulemia. As expected, mice fed a HF diet for 21 weeks had significantly elevated plasma insulin levels compared to LC fed mice, which was attenuated by BM administration ( Figure 1E ). To determine if BM treatment could prevent HF diet-induced insulin resistance, HOMA-IR was calculated. HF diet-fed mice were found to have a significantly elevated HOMA-IR compared to LC group ( Figure 1F ).
However, BM administration in HF diet fed mice significantly prevented this increase in HOMA-IR.
These results suggest that BM can prevent hyperinsulemia and insulin resistance induced by a chronic HF diet. We evaluated the effect of BM on the expression of molecules involved in insulin resistance and glucose metabolism in the liver using western blotting and RT-PCR analysis. Western blot showed that a HF diet elevated hepatic PTP1B and FOXO1, and reduced BDNF protein expression, which was significantly reversed by BM treatment (Figure 2A) . No significant differences in protein expression of SOCS3 were found between any groups (Figure 2A) . RT-PCR analysis found that a HF diet 62.02%, p = <0.001) ( Table 2 ).
Fatty acid metabolism-related genes in the liver were measured using RT-PCR in order to assess if these markers were responsible for BM's ability to prevent HF diet induced hepatic fat accumulation ( Figure 3D ). The results showed that BM prevented HF diet-induced decreases in the β oxidation gene, ACOX (HF vs. LC difference: -98.84%, p = <0.001; HF vs. BM difference: -94.02%, p = <0.001).
However the expression of ACOX was still significantly higher in the LC group compared to HF diet fed mice treated with BM (LC vs. BM difference: -80.61%, p = <0.001). Furthermore, the levels of the lipogenic genes SCD1 and FAS were significantly lower in the BM group compared to the untreated HF diet group. However, FAS expression in the LC group was significantly higher than both the HF diet group and BM group, and there were no significant differences between the LC and HF diet group in SCD1 mRNA expression. In addition, there were no significant differences between ACC mRNA expression in the HF and BM groups. However, ACC mRNA expression was significantly lower in BM treated mice compared to LC fed mice. These results suggest that BM prevents HF diet-induced fat accumulation in the liver by increasing β oxidation and inhibiting genes involved in lipogenesis. Figure 4C ). There were no significant differences in the expression of hepatic pIKK or IL-1β between the groups. In addition, nuclear protein levels of Nrf2 were significantly reduced in the livers of HF diet fed mice. However, this reduction was significantly prevented by BM treatment ( Figure 4D ). There were no significant differences in hepatic cytosolic Nrf2 protein levels among any of the groups. Furthermore, RT-PCR analysis showed a significant increase in TNFα and IL-6 mRNA expression, and decrease in Nrf2 mRNA expression in mice fed a HF diet ( Figure 4E ). The alterations in TNFα and Nrf2 mRNA levels were significantly prevented by BM administration. However, BM treatment was unable to prevent HF diet-induced elevations in IL-6 mRNA expression. No significant differences were found in the mRNA expression of IKKβ and IKKε between any of the groups. These results suggest that BM prevents the development of HF diet induced hepatic macrophage infiltration by regulating proinflammatory signalling molecules and activating Nrf2 in the liver. ). In our study, BM administration prevented HF diet induced decreases in Nrf2 protein levels in the nucleus and Nrf2 gene expression. This suggests the ability of BM to prevent HF diet induced elevations in proinflammatory signalling molecules and fat accumulation in the liver may be due to its ability to regulate the expression of the Nrf2 gene and Nrf2 nuclear protein levels.
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In conclusion, our findings suggest that chronic supplementation with BM may play an important role in preventing the actions of a HF diet in the development of inflammation, insulin resistance and hepatic steatosis in mice. A proposed model of the potential molecular mechanisms targeted by BM in mice fed a HF diet is presented in Figure 5 . Since obesity-induced inflammation and insulin resistance has been implicated in the progression of liver disease, BM may have beneficial effects in preventing the progression of HF diet induced liver steatosis. With further research and eventual human clinical trials, the possibility of using BM for the prevention of insulin resistance and associated development of hepatic steatosis appears promising. 
